Clinical TrialsInformation and insight on the latest clinical trials
- Beat AML Trial: Rapid Genetic Screening in Acute Myeloid Leukemia
Amy Burd, PhD, Vice President of Research Strategy at the Leukemia and Lymphoma Society (LLS), discusses her group’s multiarm, multisite collaborative trial which aims to test targeted therapy approaches for improving the generally poor prognosis among patients with AML.
- Potential Use of Venetoclax in Multiple Myeloma
Rod Humerickhouse, MD, PhD, asset strategy leader at AbbVie discusses the potential use of venetoclax for the treatment of patients with multiple myeloma at the 60th ASH Annual Meeting in San Diego.
- Primary Haemophagocytic Lymphohistiocytosis: Overview and New Treatment Option
Carol Satler, MD Vice President of Medical Affairs in North America for Sobi, discusses the ultra rare disease primary haemophagocytic lymphohistiocytosis (HLH) and a new FDA approved treatment Emapalumab.
- CAR-T Cell Update: Therapy Improves Outcomes for Patients With B-cell Lymphoma
Richard Thomas Maziarz, MD discusses the JULIET trial, a phase-2 study of tisagenlecleucel (marketed as KYMRIAH).
- Complications from a Hematopoietic cell Transplantation
Dr. Jonathan Peled of Memorial Sloan Kettering Cancer Center discusses his study which looked at whether pre-HCT microbiota configuration may be an important determinant of post-transplantation outcomes.
- SOBI Overview at ASH: Data from Phase 2/3 Clinical Study of Emapalumab-lzsg in Primary HLH
Rami Levin, President of North America for Swedish Orphan Biovitrum (SOBI) discusses his company’s recent FDA approval, Sobi’s commitment to the rare disease community, and how Sobi is growing its presence in North America.
- Epstein-Barr Virus Associated Post-transplant Lymphoproliferative Disorder (EBV+ PTLD)
Mohamad Mohty, MD, PhD, discusses EBV+ PTLD is an aggressive lymphoma that occurs following bone marrow transplant (also known as hematopoietic stem cell transplant, or HCT) or solid organ transplant (SOT).
- The Current State of Rett Syndrome
Daniel Glaze, Medical Director of the Blue Bird Circle Rett Center and a Professor in the Departments of Pediatrics and Neurology at Baylor College of Medicine in Houston, discusses the current state of Rett Syndrome.
- The Role of MEK Inhibitors in NF1
Annette Bakker, PhD, President and Chief Scientific Officer, of the Children’s Tumor Foundation discusses neurofibromatosis, also known as NF, is a genetic disorder that affects 1 in every 3,000 people. There are three types of NF: NF1, NF2, and schwannomatosis.
- Hemophilia: Updated Positive Interim Data from Phase 2/3 Study of Marzeptacog Alfa
Dr. Howard Levy, Chief Medical Officer of Catalyst Biosciences discusses hemophilia and his company’s post at the meeting: Updated Positive Interim Data from Its Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors.